News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘TargetedTherapy’ clear

  • One of the shortcomings of a therapy that uses millions of identical antibodies to boost the immune system's attack on cancer cells is that many patients whose tumors recede in response to the treatment also experience serious inflammatory problems, such as severe diarrhea and rashes. In a new study, a team led by Dana-Farber Cancer Institute researchers shows that giving periodic infusions of such "monoclonal" antibodies to patients who have received a widely used cancer vaccine unleashes a strong immune response to tumors, with less-harsh side effects.

Tags: Melanoma, OvarianCancer, TargetedTherapy

  • Treatment with three "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber. These risks remain low, but they should be factored in when developing patients’ treatment plans.

Tags: chemotherapy, PatientEducation, PatientSafety, TargetedTherapy

  • Dana-Farber researchers reported that patients with non-small cell lung cancer (NSCLC) whose tumor cells harbored an abnormal ALK gene responded better to targeted therapy than traditional chemotherapy.

Tags: LungCancer, TargetedTherapy

  • The National Cancer Institute (NCI) has launched a new nationwide clinical trial to find out if two molecularly targeted drugs that have improved outcomes in advanced lung cancer can increase survival of patients with early-stage lung cancer that has been surgically removed.

Tags: LungCancer, TargetedTherapy

  • Dana-Farber researchers have found that a combination of two already-in-use drugs may have an effect on stopping the growth of the most common genetic subtype of lung cancer setting the stage for clinical trials.

Tags: LungCancer, TargetedTherapy

  • Dana-Farber researchers report a novel compound has become the first targeted therapy to benefit patients with non-small cell lung cancer.

Tags: LungCancer, TargetedTherapy

  • Dana-Farber researchers have discovered how some cancer cells can evade the effect of cetuximab. This insight may explain why some cancers that initially respond to cetuximab become resistant to it, or how to overcome such resistance.

Tags: ColonCancer, EGFR, TargetedTherapy

  • A study by scientists at Dana-Farber Cancer Institute, the Broad Institute, and other research centers, may offer clues to why rates of esophageal adenocarcinomas (EACs) have risen so sharply. The findings, in Nature Genetics, point to an array of abnormal genes and proteins that may be lynchpins of EAC cell growth and therefore serve as targets for new therapies.

Tags: Genomics, TargetedTherapy

  • A new discovery by Jean Zhao, PhD, and colleagues may help physicians predict which tumors are likely to become resistant to a given drug. In the report, published by Nature Medicine, researchers described how they created a genetically engineered mouse model of human breast cancer in which the most frequently occurring breast cancer oncogene, PIK3CA, could be turned on and off.

Tags: BreastCancer, Genomics, TargetedTherapy, Genetics

  • Dana-Farber scientists found that pancreatic cancer cells' growth and spread are fueled by an unusual metabolic pathway that someday might be blocked with targeted drugs to control the deadly cancer.

Tags: PancreaticCancer, TargetedTherapy

Showing 1-10 of 42 items